Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares Outstanding (Weighted Average)
Others
Ratios

KalVista Pharmaceuticals (KALV) Operating Income: 2013-2025

Historic Operating Income for KalVista Pharmaceuticals (KALV) over the last 13 years, with Apr 2025 value amounting to -$188.0 million.

  • KalVista Pharmaceuticals' Operating Income rose 5.46% to -$45.8 million in Q2 2025 from the same period last year, while for Apr 2025 it was -$171.6 million, marking a year-over-year decrease of 66.17%. This contributed to the annual value of -$188.0 million for FY2025, which is 33.86% down from last year.
  • According to the latest figures from FY2025, KalVista Pharmaceuticals' Operating Income is -$188.0 million, which was down 33.86% from -$140.4 million recorded in FY2024.
  • KalVista Pharmaceuticals' Operating Income's 5-year high stood at -$57.9 million during FY2021, with a 5-year trough of -$188.0 million in FY2025.
  • For the 3-year period, KalVista Pharmaceuticals' Operating Income averaged around -$146.4 million, with its median value being -$140.4 million (2024).
  • Data for KalVista Pharmaceuticals' Operating Income shows a maximum YoY crashed of 66.80% (in 2022) over the last 5 years.
  • Over the past 5 years, KalVista Pharmaceuticals' Operating Income (Yearly) stood at -$57.9 million in 2021, then plummeted by 66.80% to -$96.6 million in 2022, then declined by 14.76% to -$110.9 million in 2023, then dropped by 26.67% to -$140.4 million in 2024, then tumbled by 33.86% to -$188.0 million in 2025.